Savara Inc., a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced the issuance of inducement awards to five new employees under its 2021 Inducement Equity Incentive Plan. On May 21, 2025, the company's Compensation Committee granted options to purchase a total of 85,000 shares of Savara's common stock, along with restricted stock units (RSUs) covering 75,000 shares. The stock options are priced at $2.91 per share, reflecting the closing trading price on the grant date, and feature a 10-year term with vesting occurring quarterly over four years. The RSUs will vest in full after two years, contingent on continued employment. These awards serve as a material inducement for the employees' decision to join Savara.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.